CLINICAL STUDY

OPEN ACCESS Check for updates

Development and validation of a nomogram for predicting acute kidney injury after orthotopic liver transplantation

Dandan Guo, Huifang Wang, Xiaoying Lai, Junying Li, Demin Xie, Li Zhen, Chunhui Jiang, Min Li and Xuemei Liu

Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, China

ABSTRACT

Background: We aim to develop and validate a nomogram model for predicting severe acute kidney injury (AKI) after orthotopic liver transplantation (OLT).

Methods: A total of 576 patients who received OLT in our center were enrolled. They were assigned to the development and validation cohort according to the time of inclusion. Univariable and multivariable logistic regression using the forward variable selection routine were applied to find risk factors for post-OLT severe AKI. Based on the results of multivariable analysis, a nomogram was developed and validated. Patients were followed up to assess the long-term mortality and development of chronic kidney disease (CKD).

Results: Overall, 35.9% of patients were diagnosed with severe AKI. Multivariable logistic regression analysis revealed that recipients' BMI (OR 1.10, 95% CI 1.04–1.17, p = 0.012), hypertension (OR 2.32, 95% CI 1.22–4.45, p = 0.010), preoperative serum creatine (sCr) (OR 0.96, 95% CI 0.95–0.97, p < 0.001), and intraoperative fresh frozen plasm (FFP) transfusion (OR for each 1000 ml increase 1.34, 95% CI 1.03–1.75, p = 0.031) were independent risk factors for post-OLT severe AKI. They were all incorporated into the nomogram. The area under the ROC curve (AUC) was 0.73 (p < 0.05) and 0.81 (p < 0.05) in the development and validation cohort. The calibration curve demonstrated the predicted probabilities of severe AKI agreed with the observed probabilities (p > 0.05). Kaplan-Meier survival analysis showed that patients in the high-risk group stratified by the nomogram suffered significantly poorer long-term survival than the low-risk group (HR 1.92, p < 0.01). The cumulative risk of CKD was higher in the severe AKI group than no severe AKI group after competitive risk analysis (HR 1.48, p < 0.05).

Conclusions: With excellent predictive abilities, the nomogram may be a simple and reliable tool to identify patients at high risk for severe AKI and poor long-term prognosis after OLT.

ARTICLE HISTORY

Received 16 July 2021 Revised 13 October 2021 Accepted 13 November 2021

KEYWORDS

Acute kidney injury; severe; orthotopic liver transplantation; prediction nomogram; prognosis; survival; CKD

Introduction

Acute kidney injury (AKI) is a common and significant complication after orthotopic liver transplantation (OLT), which is the only available treatment for patients with end-stage liver disease [1]. Despite advances in organ preservation, surgical techniques, and improvements in immunosuppression programs, the incidence of post-OLT AKI remains high. Probably due to inconsistent definitions of AKI in different articles, the incidence of post-OLT AKI ranges between 5% and 95%, and 8%~17% of these patients require renal replacement therapy (RRT) [2–4].

AKI has a significant influence on both short- and long-term prognosis in patients after OLT. Some

researches indicated that the mortalities of in-hospital, 30-day, and 1-year after OLT were significantly higher in patients with AKI [5]. Post-OLT AKI may also progress to a requirement for postoperative RRT, CKD, even to endstage renal disease (ESRD) [6]. Previous studies [6–10] have indicated that the long-term survival of graft and patients decreased significantly in recipients with severe AKI (KDIGO stage 2&3), compared to recipients with no or mild AKI. And severe AKI was correlated with a higher risk of CKD, heart failure, major atherosclerotic cardiovascular disease events, and all-cause death. Additionally, early initiation of CRRT was independently associated with survival benefits in recipients with severe AKI [11]. Therefore, early assessment of the risk for severe AKI is critical to improve patients' prognoses.

CONTACT Xuemei Liu 🛛 liuxuemei201718@163.com 🗈 Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The mechanism of severe AKI after OLT remains unclear. It is multifactorial involving preoperative, intraoperative, and postoperative factors. Known risk factors for AKI after OLT included recipients' BMI [12], a history of diabetes or hypertension [13,14], the Model for End Stage Liver Disease (MELD) score [15], preoperative creatinine [3], and ischemia reperfusion injury (IRI) in the graft [16].

Although many risk factors for AKI and severe AKI have been identified, their cumulative effect remains unclear. Nomogram is a visual tool that integrates multiple factors, assisting clinicians to comprehensively predict the prognosis of patients and make clinical decisions. It has been applied to predict AKI in many other clinical settings, such as nephrectomy surgery [17], cardiac surgery [18], and intracranial aneurysm clipping surgery [19], but rarely in OLT recipients. Therefore, in order to make early diagnosis and develop interventions for patients at high risk for severe AKI after OLT, a nomogram was established in this study. By integrating these included clinical factors, the nomogram could provide clinicians with an individualized estimate of the probability of severe AKI after OLT.

Methods and patients

Study population

Data from 721 patients who underwent OLT between 1 April 2013 to 31 October 2020 at the Affiliated Hospital of Qingdao University were retrospectively extracted from the electronic medical record system. Exclusion criteria included age <18 years old, diagnosed kidney diseases or RRT before OLT, fulminant hepatic failure, retransplantation, combined liver-kidney transplantation, died intraoperatively or within 48 h after surgery, and missing important data. Finally, a total of 576 patients were enrolled. The development cohort included patients who underwent OLT between 1 April 2013 and 30 April 2019, while the validation cohort was collected between 1 May 2019 and 31 October 2020 (Figure 1). The patients' privacy will not be leaked because the related data were collected through the medical record numbers rather than their names. This study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University (the ethics approval number is QYFY WZLL 26283).



Figure 1. Flow diagram of patients enrollment.

Definition

Postoperative AKI was defined according to the KDIGO criteria [20]: increase in serum creatinine (sCr) >0.3 mg/ dL (\geq 26.5 µmol/L) within 48 h or an increase in sCr to \geq 1.5 times the baseline within the first 7 days after surgery. AKI was classified into 3 stages: stage 1, sCr increase to \geq 26.5 μ mol/L or increase to 1.5–1.9-fold from baseline; stage 2, increase to 2-2.9-fold; and AKI stage 3, increase to >3-fold or ≥4.0 mg/dL $(\geq$ 353.6 µmol/L) or application of RRT. The maximum sCr level was recorded during the first 7 days after surgery and compared to the baseline level. The most recent preoperative laboratory results were used as the baseline. Stages 2&3 were called severe AKI. The formula for the Model for End-Stage Liver Disease (MELD) score is: $3.8 \times \log_{e}(\text{bilirubin } [\text{mg/dL}]) + 11.2 \times \log_{e}(\text{INR})$ + $9.6 \times \log_{e}(sCr [mg/dL]) + 6.4 \times (etiology: 0 if choles$ tatic or alcoholic, 1 otherwise) [21]. The estimated glomerular filtration rate (eGFR) was calculated according to the Modification of Diet in Renal Disease (MDRD) equation [22]. CKD was defined as eGFR <60 mL/min/ 1.73 m² for 3 months, regardless of the presence or absence of structural kidney damage [23]. Hypertension was defined as the mean systolic BP \geq 140 mm Hg, the mean diastolic BP ≥90 mm Hg, and/or current treatment with antihypertensive medication [24].

Outcome

Previous studies [6–10] have indicated that mainly severe AKI (KDIGO stage 2&3) has an impact on the long-term survival and occurrence of CKD. Therefore, we chose severe AKI as an outcome event in this prediction model. The long-term prognosis of patients, focusing on mortality and the development of CKD, was also monitored. The follow-up was completed in March 2021 through outpatient or telephone consultations.

Covariates

Preoperative recipient factors included sex, age, BMI, personal histories of smoking and alcoholism, comorbidities (e.g., hypertension or diabetes mellitus), etiologies for OLT (viral hepatitis, hepatocellular carcinoma, alcohol-related liver disease, cholestatic liver disease, and others), MELD score, Child-Pugh score, hepatic decompensation (e.g., encephalopathy and ascites), preoperative left ventricular ejection fraction (LVEF), and preoperative laboratory variables (routine blood test, coagulation markers, blood electrolytes , and blood biochemical examinations).

Intraoperative factors included surgical duration, anhepatic time, graft-recipient body weight ratio (GRWR), blood loss and average blood loss per kilogram of body weight, intraoperative medication (ulinastatin, furosemide, and insulin), amount of blood product transfused (RBC, fresh frozen plasma (FFP), cryoprecipitate, platelet concentrate, and salvage blood), fluid administration (crystalloid and colloidal solution).

Postoperative clinical outcome variables included the requirement for RRT, length of postoperative hospital stay, length of ICU stay, and mortality of in-hospital.

Sample size

The effective sample size in prediction research (development and validation) was determined by the number of outcome events. It was defined to have at least 10 outcome events per variable (EPV) to ensure accuracy [25]. Based on the documented prevalence of severe AKI in the literature of 30.7–41% [7,26–28], especially the incidence of 35.6% in our center from the previous literature, we expected a 35% event rate for severe AKI in this study. In order to allow 10 or fewer predictors in the final multivariable logistic regression model, we estimated that 286 patients or more were required. Our sample size and the number of outcome events far exceed the EPV method and therefore was expected to provide reliable estimates.

Statistical analyses

R version 4.0.3 (R Foundation for Statistical Computing) and STATA 15.0 (StataCorp Texas, TX) were used to analyze the data. The Kolmogorov-Smirnov test was performed to examine the normality of the data. Median and interquartile range (IQR) were used to describe continuous variables and comparisons were performed using the Mann–Whitney U test. Categorical variables were expressed in quantities and percentages and comparisons were made using the Chi-square test or Fisher's exact test. The univariable logistic regression was used to evaluate the association between perioperative factors and severe AKI in the development cohort. Variables with p < 0.05 were included in the multivariable logistic regression. The final multivariable logistic regression model was seriously chosen by using forward stepwise regression with Akaike's information criterion (AIC) as the stopping rule [29]. The AIC value for the final model was minimized with the fewest number of variables. Multicollinearity variables were not incorporated into the multivariable logistic

regression analysis, which was estimated by the variance inflation factor (VIF) with a reference value of 10 [26]. For further analysis, a nomogram was developed based on the results of the multivariable logistic regression analysis. Then, we validated the predictive ability of this model by examining discrimination and calibration in the development cohort and validation cohort. The discrimination was quantified by the area under the receiver operating characteristic (ROC) curve (AUC). The calibration was evaluated by the calibration curve [30]. The long-term survival was estimated using Kaplan-Meier analysis, with comparisons between groups made using log-rank test. The CKD incidence and mortality before CKD were assessed by the cumulative incidence function methods and Fine - Gray models, with death handled as a competing event. The 'rms' package was used for the nomogram and calibration curve. The 'survminer' and 'survival' packages were used for Kaplan-Meier analysis. For all statistical analyses, p-values of < 0.05 were considered statistically significant.

Results

Basic characteristics

A total of 576 recipients were enrolled in the final study population, including 423 patients in the development cohort and 153 patients in the validation cohort. The basic characteristics of the recipients in the development and validation cohorts were shown in Table 1. According to the KDIGO criteria, the incidence of severe AKI was 34.3% and 40.5% in the development and validation cohort, respectively (p > 0.05).

The median age of all recipients was 52 (45–59) years, with 81.9% were male. The most common etiology for OLT was hepatocellular carcinoma combined with HBV (45.4%) followed by HBV-related hepatic cirrhosis (26.9%). Overall, 71.4% of patients were subsequently diagnosed with AKI after OLT, and the incidence of stage 1, stage 2, and stage 3 AKI was 35.8%, 20.3%, 15.6%, respectively. 7.8% of patients required postoperative RRT. 44.3% of AKI occurred at the first postoperative day (POD), 25.8%, 13.2%, 6.8%, 3.5%, 4.0% and 2.4% of AKI occurred at POD 2 to POD 7, respectively.

Logistic regression analysis for predictors of severe AKI after OLT

Univariable logistic analysis was performed in the development cohort to select risk factors for post-OLT severe AKI. The variables with p < 0.05 and several factors with clinical significance in previous researches were all included in the multivariable logistic regression, such as operation time and RBC transfusion, etc [7,31]. Afterward, the final regression model was obtained according to the minimum value of AIC with the fewest number of variables. Finally, recipients' BMI (OR 1.10, 95% CI 1.04–1.17, p = 0.012), hypertension (OR 2.32, 95% CI 1.22–4.45, p = 0.010), preoperative sCr (OR 0.96, 95% CI 0.95–0.97, p < 0.001), and intraoperative FFP transfusion (OR for each 1000 ml increase 1.34, 95% CI 1.03–1.75, p = 0.031) were independent risk factors for post-OLT severe AKI (Table 2).

Development and validation of the nomogram model

A nomogram for predicting the possibility of severe AKI after OLT was formulated using the results of the multivariable logistic regression (Figure 2). Points were assigned to the four identified predictors based on their regression coefficients. Add up the points of each factor decided by individuals to calculate the estimated possibility of severe AKI after OLT. Then, the nomogram was validated in the development cohort and validation cohort. The discrimination was quantified with area under the ROC curve (AUC), which was 0.73 (95% Cl: 0.68–0.78, *p* < 0.05) in the development cohort and 0.81 (95% CI: 0.74–0.88, *p* < 0.05) in the validation cohort (Figure 3). The optimal cutoff value of the nomogram model to identify patients at high-risk for severe AKI was 0.36 according to the Youden index, which was determined based on the optimization of sensitivity and specificity through ROC analysis. The sensitivity and specificity of the model were 0.66 and 0.70 in the development cohort, and 0.79 and 0.78 in the validation cohort. The calibration curve of the nomogram was presented in Figure 4, which demonstrated that the severe AKI probabilities predicted by the nomogram agreed with the observed probabilities (p > 0.05). These results indicated that the nomogram model could accurately predict the risk of severe AKI after OLT.

Short-term prognosis of patients with and without severe AKI

The in-hospital mortality of patients with severe AKI was approximately 4.25 times that of patients without severe AKI (p = 0.003). Postoperative RRT was required in 14.0% of patients with severe AKI and 4.3% of patients without severe AKI (p < 0.001). When compared with patients without severe AKI, the ICU stay

Table 1. Perioperative characteristics of patients between development and validation cohort.

Demognaphic data get (var) Ada (Wa) Age (var) Ada (Wa) Ada (Wa) Ad	Characteristic	Development data ($n = 423$)	Validation data ($n = 153$)	<i>p</i> -Value
Age (ward) 53 (45–59) 52 (45–59) 0.44 Male (M,Sh) 347 (82.0%) 12 (81.7%) 0.90 BWI (Kg/m) 19.33 (82.0%) 12 (81.7%) 0.90 Sinching (MS) 191 (42.2%) 58 (77.9%) 0.33 Alcohalim (MS) 191 (42.8%) 70 (45.8%) 0.92 Pathogenesis of liver disease 1 12 (79.1%) 0.32 HW hepatits (MS) 10 (74.7%) 12 (79.1%) 0.32 HW hepatits (MS) 30 (74.9%) 12 (79.1%) 0.32 HW hepatits (MS) 30 (74.9%) 7 (45.6%) 0.01 Deter (MS) 30 (74.9%) 7 (45.6%) 0.01 Deter (MS) 30 (74.9%) 7 (42.2%) 0.07 Deter (MS) 30 (74.9%) 7 (42.2%) 0.07 Deter (MS) 30 (74.9%) 7 (42.2%) 0.07 Deter (MS) 31 (12.9%) 30 (13.1%) 1.00 Addition (MS) 31 (12.5%) 24 (15.7%) 0.33 Deter (MS) 33 (12.5%) 24 (15.7%) 0.33	Demographic data			
Male (M/N) 347 (82.0%) 125 (81.7%) 0.95 MAR (mmrlg) 91.33 (84.67-90.00) 91.33 (84.67-90.00) 0.35 MAR (mmrlg) 91.33 (84.67-90.00) 91.33 (83.67-97.00) 0.85 Photopersion (M/N) 191 (45.2%) 70 (45.8%) 0.92 Photopersion (M/N) 9 (17.6%) 0.13 0.13 Attonolosm (M/N) 191 (45.2%) 70 (45.8%) 0.92 Photopersion (M/N) 9 (21.7%) 6.33 0.24 Photopersion (M/N) 9 (21.7%) 6.33 0.24 Photopersion (M/N) 9 (17.7%) 6.3 0.24 Photopersion (M/N) 9 (17.7%) 8.3 0.45 Photopersion (M/N) 10 (07.3%) 8.3 0.46 Uver complectance (M/N) 35 (13.0%) 20 (13.1%) 1.0 Diabeters mellitics (M/N) 33 (15.6%) 24 (15.7%) 0.33 Genome metal disease (M/N) 13 (1.5%) 2.4 (15.7%) 0.33 Genome metal disease (M/N) 13 (1.5%) 2.4 (15.7%) 0.33 Diabeters mellitics (M/N) <td>Age (years)</td> <td>53 (45–59)</td> <td>52 (45–59)</td> <td>0.44</td>	Age (years)	53 (45–59)	52 (45–59)	0.44
BM (Kgm ²) 24.09 (21.95-29.5) 24.24 (21.45-71.6) 0.35 Personal Instary 913 (45.29.0) 913 (45.29.0) 913 (45.29.0) 914 (45.29.0)	Male (N,%)	347 (82.0%)	125 (81.7%)	0.90
MAP PH2304 91.33 (84.67-90.00) 91.33 (83.67-97.00) 0.64 Smoking (MA) 19 (45.2%) 58 159 0.13 Phappenesis (MA) 19 (45.2%) 71 (45.9%) 0.13 Phappenesis (MA) 121 (79.1%) 0.32 (45.9%) 0.24 Accholic Iwe circhoss (MA) 40 (11.1%) 8 6.2.3%) 0.03 Pestatic Bitics circhosa (MA) 20 (47.3%) 8 6.2.3%) 0.03 Pestatic Bitics circhosa (MA) 30 (7.1%) 7 (4.5%) 0.34 Chemer (MA) 31 (12.5%) 20 (13.1%) 0.00 Assites > 11 (MA) 51 (13.5%) 0.33 11 13.1%) 5 0.33 Properative Diversition (MA) 53 (12.6%) 13 24 15.7%) 0.33 Contraw (MA) 13 13.1%) 5 13.3% 0.00 5 Diabetes melitics (MA) 13 13	BMI (Kg/m²)	24.09 (21.95–25.95)	24.24 (21.45–27.16)	0.36
Personal history Sinching (We) Sin (Ve)	MAP (mmHg)	91.33 (84.67–98.00)	91.33 (83.67–97.00)	0.68
Sincensity (Ms) 19 10	Personal history			
Recording (n, n) (D) (D) (D) (D) HW pensits (NS) 36 (74.7%) 12 (79.1%) 6 (3.9%) 0.24 Alcohol: New crimbis (NS) 47 (11.1%) 8 (5.2%) 0.057 Heptacellular carcinoms (NS) 20 (47.3%) 83 (5.2%) 0.057 Heptacellular carcinoms (NS) 43 (10.2%) 16 (10.5%) 0.058 Liver complication 20 (31.9%) 20 (31.9%) 0.33 Specifier modellar sciences 9 (25.9%) 24 (15.7%) 0.33 Diabetism melitics (NS) 13 (15.9%) 24 (15.7%) 0.33 Diabetism melitics (NS) 13 (15.9%) 24 (15.7%) 0.33 Diabetism melitics (NS) 13 (15.9%) 22 (20.9%) 0.23 Coronary heart disease (N/%) 10 (26.0%) 32 (20.9%) 0.23 Prooperative Network (NS) 23 (25.7%) 13 (26.9%) 0.03 Prooperative Network (NS) 23 (25.7%) 13 (26.9%) 0.03 Prooperative Network (NS) 23 (25.7%) 13 (26.9%) 0.03 Prooperative Network (NS) 23 (25.7%)	Smoking (N,%)	191 (45.2%)	58 (37.9%)	0.13
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Alconolism (N,%) Dathaganasis of liver disease	191 (45.2%)	70 (45.8%)	0.92
HC (hegasitis (Ma) -9 (2.1%) 16 (3.9%) 0.24 Acholic law carchons (MA) 47 (1.1%) 8 (3.2%) 0.017 Hepatocellular carchons (MA) 20 (47.3%) 7 (4.6%) 0.34 Cholestati Casco (MA) 30 (7.3%) 7 (4.6%) 0.34 Cher (MA) 31 (1.2%) 16 (10.5%) 0.88 Encephalopathy (MA) 11 (2.2%) 37 (2.42%) 0.67 Baseline medical status 0 11 (2.2%) 37 (2.42%) 0.67 Baseline medical status 0 24 (15.7%) 0.33 11 (3.5%) 0.33 Properative NMA) 10 (2.6%) 24 (15.7%) 0.33 13 (1.5%) 0.33 Addominal supper history (MA) 10 (2.6%) 24 (1.5.7%) 0.35 Properative supper history (MA) 10 (2.6%) 12 (2.3%) 0.35 Properative supper history (MA) 10 (2.6%) 12 (2.5%) 0.35 Properative supper history (MA) 10 (2.6%) 12 (2.6%) 0.55 Properative supper history (MA) 10 (2.6%) 7 (4.7%) 0.66	HBV hopstitis (N %)	316 (74 7%)	121 (70.1%)	032
$\begin{array}{llllllllllllllllllllllllllllllllllll$	HCV hepatitis (N %)	9 (2 1%)	6 (3.9%)	0.32
Hepatocellular carcinoma (Wsh) 200 (47.38) 78 (54.28) 0.16 Cholestati Gase (Wsh) 30 (7.18) 7 (4.6%) 0.38 Uter complications T T 16 (15.5%) 0.88 Acstes > 11 (Wsh) 11 (26.2%) 37 (24.2%) 0.67 Baseline medical status T 0 0.33 0.33 typerension (Wsh) 31 (25.9%) 24 (15.7%) 0.33 typerension (Wsh) 31 (25.9%) 24 (15.7%) 0.33 typerension (Wsh) 10 (26.0%) 32 (20.9%) 0.20 Abdominal supper history (Wsh) 10 (26.0%) 32 (20.9%) 0.05 Preoperative cores T 10 (26.0%) 32 (20.9%) 0.05 Preoperative cores T 10 (26.0%) 12 (20.9%) 0.05 Cores 12 (7.19, 7.3-17.95) 13.26 (96.8-18.28) 0.06 Child Case (Vsh) 20 (46.2%) 76 (49.7%) 0.61 Cores 12 (10, 0%) 20 (46.2%) 76 (49.7%) 0.61 Cores 12 (10, 0%) 20 (23.2%) </td <td>Alcoholic liver cirrhosis (N.%)</td> <td>47 (11.1%)</td> <td>8 (5.2%)</td> <td>0.037</td>	Alcoholic liver cirrhosis (N.%)	47 (11.1%)	8 (5.2%)	0.037
	Hepatocellular carcinoma (N,%)	200 (47.3%)	83 (54.2%)	0.16
Other (M(%) 16 (10.5%) 0.88 Encephalopathy (M(%) 55 (13.0%) 20 (13.1%) 1.00 Ascites > 11 (26.2%) 37 (24.2%) 0.67 Baseline medical status 7 24.1% 0.33 Preperative IN(%) 33 (19.6%) 24 (15.7%) 0.33 Strainer Micking (M(%)) 13 (13.1%) 5 (13.3%) 1.00 Abdominal surgery history (M(%) 10 (26.0%) 22 (52.1%) 12 (29.5%) 0.23 Preoperative INTE (M) 22 (25.1%) 13 (13.%) 0.5 0.05 Preoperative INTE (M) 23 (22.1%) 47 (130.7%) 0.7 0.7 Preoperative INTE (M(%) 10 (13.7%) 0.7 <td< td=""><td>Cholestatic disease (N,%)</td><td>30 (7.1%)</td><td>7 (4.6%)</td><td>0.34</td></td<>	Cholestatic disease (N,%)	30 (7.1%)	7 (4.6%)	0.34
Liver complications Encephilograph (y(%) Series > 1L (W%) Series > 1L (W%) Series > 1L (W%) Biseline medical status Diabetes mellitus (W%) Diabetes mellitus (W%) Sa (12,5%) Actines > 1L (W%) Sa (12,5%) Diabetes mellitus (W%) Sa (12,5%) Actines mellitus (W%) Sa (12,5%) Actines (W%) Actines (W%) Actines (W%) Sa (12,5%) Preoperative (WF (%) Preoperative (WF) Preoperative mellective (Freeport blockers (W%) Diabetes (W%) Sa (12,5%) Preoperative (WF) Preoperative (WF) Preoperative (WF) Preoperative (WF) Preoperative (W%) Diabetes (W%) Actines (W	Other (<i>N</i> ,%)	43 (10.2%)	16 (10.5%)	0.88
Encephalopathy (M,%) 55 (13.0%) 20 (13.1%) 0.067 Baseline medical status 7 (24.2%) 0.67 Diabetes medical status 7 (24.2%) 0.33 hypertension (M,%) 53 (12.5%) 24 (15.7%) 0.33 oconary hear disease (M,%) 13 (3.1%) 25 (3.5%) 0.33 hypertension (M,%) 53 (12.5%) 24 (15.7%) 0.33 oconary hear disease (M,%) 110 (22.0%) 25 (25.%) 0.03 Pacoparative diversion (M,%) 23 (22.%) 45 (05.%%) 0.03 Propoparative conneclecture B receptor blockers (M,%) 123 (29.1%) 47 (30.7%) 0.06 MELD >20 (M,%) 30 (19.6%) 84 (19.9%) 1.00 0.66 Child cask (M,%) 2 (21.1%) 5 (3.3%) 0.66 A 9 (2.1%) 5 (4.9.7%) C C 210 (49.6%) 76 (49.7%) C C 20 (44.6%) 76 (49.7%) C C 210 (49.6%) 22.9 (1.4.2.3.7) 0.48 Propearative soboratory data 10.00 0.0	Liver complications			
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Encephalopathy (N,%)	55 (13.0%)	20 (13.1%)	1.00
easesting method: 3 status hypertension (N,%) 33 (12,5%) 24 (15,7%) 0.33 hypertension (N,%) 5 (15,7%) 24 (15,7%) 0.33 cronary hear disease (N,%) 13 (3,1%) 5 (13,5%) 0.33 hypertension (N,%) 2 (15,7%) 22 (20,%) 0.33 hypertension (N,%) 2 (15,7%) 10 (26,0%) 22 (20,%) 0.33 Preoperative Inverse (Freeptor blockers (N,%) 2 (15,7%) 10 (26,0%) 10 (25,2%) 15 (9,2%) 0.055 Preoperative inverse (N,%) 2 (15,7%) 14 (10,2%) 0.055 Preoperative inverse (N,%) 12 (15,7%) 14 (10,2%) 0.055 Preoperative inverse (N,%) 12 (15,7%) 14 (10,2%) 0.055 Preoperative inverse (N,%) 10 (19,6%) 10 (19,	Ascites $> 1L(N,\%)$	111 (26.2%)	37 (24.2%)	0.67
Diducts Intellius (h, %) 63 (1957) 24 (15,78) 0.33 Coronay hear disease (h/%) 13 (15,78) 5 (15,78) 0.33 Coronay hear disease (h/%) 13 (15,78) 5 (15,78) 0.33 Andominal surger hilos (h/%) 12 (0,78) 15 (20,78) 0.33 Preoperative invise(h/%) 12 (0,73) 47 (0,78) 0.37 Preoperative invise(h/%) 12 (2,1%) 47 (0,78) 0.66 Preoperative invise(h/%) 12 (2,1%) 47 (0,78) 0.66 Preoperative invise(h/%) 12 (2,1%) 5 (3,3%) 0.66 MED score 9 (2,1%) 5 (3,3%) 0.61 A 9 (2,1%) 5 (3,3%) 0.62 A 9 (2,1%) 5 (3,4,1,0) 0.62 A 9 (2,1%) 2.29 (16,4,6,7,3) 0.82	Baseline medical status	82 (10 60/)	24 (15 70/)	0.22
$\begin{array}{c} \label{eq:constraint} \mbox{Trans} \m$	Hypertension (N %)	53 (12.5%)	24 (13.7%) 24 (15.7%)	0.33
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Coronary heart disease (N%)	13 (3 1%)	5 (3 3%)	1.00
Preoperative LVEF (%) Constraint Cols Cols <t< td=""><td>Abdominal surgery history (N.%)</td><td>110 (26.0%)</td><td>32 (20.9%)</td><td>0.23</td></t<>	Abdominal surgery history (N.%)	110 (26.0%)	32 (20.9%)	0.23
Preoperative nonselective () 122 (52%) 15 (9.8%) 0.055 Preoperative scores 122 (9.1%) 47 (30.7%) 0.76 MED score 122 (9.1%) 47 (30.7%) 0.76 MED score 9 (8-13) 9 (8-14) 0.55 Child-bugh score 9 (8-13) 9 (8-14) 0.58 Child-bugh score 9 (2.1%) 5 (3.3%) 0.61 A 204 (48.2%) 76 (49.7%) 0.61 A 204 (48.2%) 76 (49.7%) 0.61 Minte blood cell(x: 10 ⁹ /L) 2.39 (1.5-3.82) 2.29 (1.42-3.77) 0.48 Lymphortex (1.6%) 2.29 (1.42-3.77) 0.48 0.51 Minte blood cell(x: 10 ⁹ /L) 2.69 (2.45-3.57) 2.96 (2.49-3.59) 0.82 Memophils(x: 10 ⁹ /L) 2.69 (2.45-3.57) 2.96 (2.49-3.59) 0.82 Hemoglobin (g/L) 91 (77-110) 91 (77-111) 0.91 Hemoglobin (g/L) 582 (54-61-33) 935 (54-66-27) 0.65 Albumin (g/L) 556 (31.47-39.02) 3.43 (32-32-43) 0.38 Total proten (Preoperative LVEF (%)	62 (60, 65)	62 (60, 64)	0.37
Preoperative divertics (M/%) 123 (29,1%) 47 (30.7%) 0.76 MELD score 12.71 (9.73–7755) 13.26 (9.68–18.28) 0.46 MELD > 20 (M%) 30 (19.6%) B4 (19.9%) 1.00 Child Pugh score 9 (8–13) 9 (8–14) 0.58 Child class (M/%) 76 (49.7%) 76 (49.7%) 6 C 210 (49.6%) 72 (47.1%) 0.61 Preoperative laboratory data 72 (21.5%) 5 (3.3%) 0.61 Preoperative laboratory data 72 (14.9.1%) 76 (49.7%) 0.62 Preoperative laboratory data 72 (14.9.1%) 0.65 (0.41-0.66) 0.62 (0.41-0.39) 0.62 Hemoglobin (g/L) 2.96 (2.45-3.57) 2.96 (2.45-3.57) 0.48 0.76 Hemoglobin (g/L) 91 (77-110) 91 (77-111) 0.91 14.3-1000 0.38 Total protein (g/L) 58.67 (5.421-63.3) 58.45 (5.42,-6.2.7) 0.65 0.88 15.86 (0.58-49.89) 0.55 BUL (urmol/L) 17.16 (5.5-49.89) 15.58 (0.58-43.6) 0.65 111 71 (4.3-100.0) 0.77	Preoperative nonselective β receptor blockers (N,%)	22 (5.2%)	15 (9.8%)	0.055
Preperative scores preperative scores 12.71 (9.73–17.95) 13.26 (9.68–18.28) 0.46 MELD > 20 (N/sh) 30 (19.6%) 84 (19.9%) 1.00 A 9 (2.1%) 5 (3.3%) 0.61 A 9 (2.1%) 76 (49.7%) 2.05 B 2.04 (48.2%) 76 (49.7%) 2.05 Preoperative laboratory data 72 (47.1%) 70 (49.7%) 2.35 (2.35–5.34) 3.38 (2.26–5.28) 0.50 Neutrophils, 10 ⁶⁷ /1 2.35 (2.45–5.37) 2.36 (2.49–3.59) 0.82 1.42–3.77) 0.48 Lymphocyte(x 10 ⁷ /1) 2.56 (2.4–3.57) 2.96 (2.49–3.59) 0.82 1.42–3.77) 0.48 Lymphocyte(x 10 ⁷ /1) 0.65 (0.4–1.06) 0.62 (0.4–0.98) 0.22 1.42–3.77) 0.48 Lymphocyte(x 10 ⁷ /1) 0.65 (0.4–1.06) 0.62 (0.4–0.98) 0.22 1.42–3.77) 0.48 Lymphocyte(x 10 ⁷ /1) 0.65 (0.4–1.06) 0.62 (0.4–0.98) 0.22 0.71 (2.3–3.26) 0.76 Hemoglobin (g/L) 91 (77–110) 91 (77–111) 0.91 0.76 1.44 0.71<	Preoperative diuretics (N,%)	123 (29.1%)	47 (30.7%)	0.76
MELD score 12.71 (9.73–17.95) 13.26 (9.68–18.28) 0.46 MELD > 20 (M/s) 30 (19.6%) 64 (19.9%) 1.00 Child Chass (M/s) 9 (8–13) 9 (8–14) 0.61 B 204 (48.2%) 76 (49.7%) 0.61 C 210 (49.6%) 72 (47.1%) 0.61 Preoperative laboratory data White blood cell(× 10 ⁷ /L) 2.35 (2.35–5.34) 3.38 (2.26–5.28) 0.50 Neutrophils(× 10 ⁷ /L) 2.39 (1.5–3.82) 2.29 (1.42–3.77) 0.48 Hemoglobin (g/L) 9 (2.13) 2.96 (2.45–3.57) 2.96 (2.49–3.59) 0.82 RBC (× 10 ¹² /L) 2.66 (2.45–3.57) 2.96 (2.49–3.59) 0.82 0.76 Hemoglobin (g/L) 9 (3–11) 71 (4.3–108) 0.38 0.76 Platel (× 10 ⁴ /L) 64 (39–111) 71 (4.3–108) 0.38 0.76 Total protein (g/L) 58.87 (54.21–63.3) 58.55 (54.6–6.27) 0.65 Albumin (g/L) 37.36 (21.6–5.50.7) 3.59 (21.4–4.21.2) 0.63 DBL (µmol/L) 17.16 (9.55–49.89) 15.58 (9.56–4.3.6) 0	Preoperative scores			
$\begin{array}{c} {\rm MELD} > 20 \ (M,\%) & 30 \ (19.6\%) & 84 \ (19.9\%) & 1.00 \\ {\rm Child class} \ (M,\%) & 9 \ (B-13) & 9 \ (B-14) & 0.58 \\ {\rm Child class} \ (M,\%) & 76 \ (49.7\%) & 0.61 \\ {\rm A} & 9 \ (2.1\%) & 76 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 70 \ (49.7\%) & 71 \ (43.736) & 70 \ (49.7\%) & 71 \ (43.736) & 71 $	MELD score	12.71 (9.73–17.95)	13.26 (9.68–18.28)	0.46
Child Hay Gyn Score 9 (B-13) 9 (B-14) 0.58 A 9 (2,1%) 5 (3.3%) 0.61 A 9 (2,1%) 5 (3.3%) 0.61 B 204 (48,2%) 76 (49.7%) C C 210 (49.6%) 72 (47.1%) 0.50 Preoperative laboratory data 338 (2.35–5.34) 338 (2.26–5.28) 0.50 Neutrophils(~ 10 ⁹ /L) 2.39 (1.5–3.82) 2.29 (1.42–3.77) 0.48 Lymphocyte(× 10 ⁹ /L) 0.65 (0.4–1.06) 0.62 (0.4–1.08) 0.22 RBC (× 10 ¹⁷ /L) 2.96 (2.49–3.59) 0.82 0.83 Hemoglobin (g/L) 91 (77–110) 91 (77–111) 0.91 Hemosolin (g/L) 2.65 (23–32) 2.71 (23.3–3.2.6) 0.76 Dable (urmol/L) 63 (31.87–30.02) 34.43 (62.32–7.49) 0.55 DBle (urmol/L) 16 (31.62–45.07) 18.06 (11.51–4.09.3) 0.66 BlL (urmol/L) 17.16 (9.55–44.807) 15.86 (9.8–4.3.6) 0.65 BlL (urmol/L) 18 (38 (1.62–4.57) 16.36 (11.51–4.09.3) 0.77 DA (U/L)<	MELD > 20 (N,%)	30 (19.6%)	84 (19.9%)	1.00
Child Class (W,%) 001 A 9 (2.1%) 5 (3.3%) B 204 (48.2%) 76 (49.7%) C 210 (49.6%) 72 (47.1%) Preoperative laboratory data 5 (3.3%) 0.5 White blood cell(x 10 ⁹ /L) 3.58 (2.35–5.34) 3.38 (2.26–5.28) 0.50 Neutrophils(x 10 ⁹ /L) 2.39 (1.5–3.82) 2.29 (1.42–3.77) 0.48 Lymphocyte(x 10 ⁷ /L) 2.05 (2.45–3.57) 2.05 (2.43–3.50) 0.82 Hemoglobin (g/L) 91 (77–110) 91 (77–111) 0.91 Hematocrit (%) 2.63 (2.43–3.57) 2.86 (4.6–2.7) 0.65 Albumin (g/L) 56 (3.18.7–30.2) 3.44 (3.23–3.49) 0.15 Total protin (g/L) 35 67 (3.18.7–39.02) 3.44 (3.23–3.7.49) 0.15 Bill (µmol/L) 17.16 (9.55–49.89) 15.58 (9.56–4.62.7) 0.63 Dill (µmol/L) 17.16 (9.55–49.89) 15.58 (9.56–4.62.7) 0.63 Bill (µmol/L) 17.16 (9.55–49.89) 15.8 (9.56–4.62.7) 0.63 Bill (µmol/L) 17.16 (9.55–49.89) 15.8 (9.56–4.62.7) 0.63 </td <td>Child-Pugh score</td> <td>9 (8–13)</td> <td>9 (8–14)</td> <td>0.58</td>	Child-Pugh score	9 (8–13)	9 (8–14)	0.58
A 9 (2.1%) 5 (3.3%) B 204 (48.2%) 76 (49.7%) C 210 (49.6%) 72 (47.1%) Preoperative laboratory data 3.88 (2.35–5.34) 3.38 (2.26–5.28) 0.50 White blood cell(× 10 ⁶ /L) 2.39 (15–3.32) 2.29 (1.42–3.77) 0.44 Lymphocyte(× 10 ⁶ /L) 0.65 (0.4–1.06) 0.62 (0.41–0.98) 0.22 BBC (× 10 ⁶ /L) 2.96 (2.45–3.57) 2.96 (2.49–3.59) 0.82 Hemoglobin (g/L) 91 (77–110) 91 (77–111) 0.91 Hemoglobin (g/L) 2.69 (23–32) 2.71 (23.3–32.6) 0.76 Platelet (× 10 ⁶ /L) 64 (39–111) 71 (43–108) 0.38 Total protein (g/L) 35.67 (31.87–39.02) 34.43 (32.32–7.49) 0.15 BBL (µmo/L) 17.16 (955–49.49) 15.88 (95.4–6.2.7) 0.66 BBL (µmo/L) 17.16 (955–49.49) 15.88 (95.4–4.62.7) 0.63 BBL (µmo/L) 17.16 (955–49.49) 15.88 (95.4–4.62.7) 0.63 BBL (µmo/L) 17.16 (955–49.49) 15.89 (95.4–4.36) 0.65 BBL (µmo/L)	Child class (N,%)	0 (2 10()	F (2, 20()	0.61
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	A	9 (2.1%)	5 (3.3%) 76 (40.7%)	
Preoperative laboratory data If (19,00,0) If (19,00,0) Preoperative laboratory White blood cell(× 10 ⁰ /L) 3.58 (2.35–5.34) 3.38 (2.26–5.28) 0.50 Neutrophil(× 10 ⁰ /L) 2.39 (1.5–3.82) 2.29 (1.42–3.77) 0.48 Lymphocyte(× 10 ³ /L) 0.65 (0.4–1.06) 0.62 (0.41–0.98) 0.22 REC (× 10 ³ /L) 2.66 (2.45–3.57) 2.96 (2.49–3.59) 0.82 Hemoglobin (g/L) 91 (77–110) 91 (77–111) 0.91 Hematocrit (%) 2.69 (2.3–32) 2.71 (2.3–3.2.6) 0.76 Platelet (× 10 ³ /L) 64 (39–111) 71 (43–108) 0.38 Total protein (g/L) 35.67 (31.87–39.02) 34.43 (2.3–3.74) 0.15 TBL (µmol/L) 17.68 (95–49.09) 15.58 (9.58–43.6) 0.65 DBL (µmol/L) 18.88 (11.62–45.07) 18.06 (11.51–40.93) 0.76 ALT (V/L) 27 (17–51) 26 (18–49) 0.71 AST (U/L) 182 (35–571) 45 (3.46–5.47) 0.31 DH (µmol/L) 458 (3.6–5.91) 45 (3.46–5.47) 0.33 U/L 17.64 (9.3.6–15	B C	204 (48.2%)	70 (49.7%) 72 (47.1%)	
White blood cell($\times 10^9/L$)3.58 (2.35–5.34)3.38 (2.26–5.28)0.50Neutrophils($\times 10^9/L$)2.39 (1.5–3.82)2.29 (1.42–3.77)0.48Lymphocytex($\times 10^9/L$)0.65 (0.4–1.06)0.62 (0.4–1.038)0.22RBC ($\times 10^{12}/L$)2.96 (2.45–3.57)2.96 (2.49–3.59)0.82Hemoglobin (g/L)91 (77–110)91 (77–111)0.91Hemoglobin (g/L)26.9 (2.3–32)27.1 (2.3–3.2.6)0.76Platelet ($\times 10^9/L$)64 (39–111)71 (43–108)0.38Total protein (g/L)35.67 (3.187–39.02)34.43 (3.2.2.37.49)0.15Bll (umo/L)37.36 (21.6–95.07)35.91 (21.44–8.2.12)0.63DBL (umo/L)17.16 (9.55–49.89)15.58 (9.58–4.3.6)0.65ALT (U/L)17.16 (9.55–49.89)15.58 (9.58–4.3.6)0.65ALT (U/L)17.16 (9.55–49.89)15.58 (9.58–4.3.6)0.65BlL (umo/L)18.88 (11.62–45.07)18.06 (11.51–4.0.93)0.76ALT (U/L)27 (17–51)26 (18–49)0.71AST (U/L)38 (2.5–74)37 (25–61)0.31DH (U/L)18 (4.6–5.07)0.330.37BUN (nmo/L)4.58 (3.6–5.91)4.5 (3.46–5.47)0.25Scr (umo/L)64 (51–77)63 (50–77)0.33UA (umo/L)18.48 (3.2–2.155)12.015 (90.35–147.30)0.91Prothrombin time (s)16.3 (14.1–2.04)16.3 (14.2–2.02)0.90INR1.42 (12–1.79)1.4 (1.2–1.82)0.55Na ⁺ (mmo/L)3.88 (3.58–4.21)3.87 (3.5–4.13)0.5	Preoperative laboratory data	210 (49.070)	72 (47.170)	
Neutrophils(x 10 ⁹ /L) 2.39 (1,5–3.82) 2.29 (1,42–3.77) 0.48 Lymphocyte(x 10 ⁹ /L) 0.65 (0.4–1.06) 0.62 (0.41–0.98) 0.22 RBC (x 10 ¹² /L) 2.96 (2,45–3.57) 2.96 (2,49–3.59) 0.82 Hemoglobin (g/L) 91 (77–110) 91 (77–111) 0.91 Hematocrit (%i) 26.9 (23–32) 27.1 (23.3–32.6) 0.76 Platelet (x 10 ⁹ /L) 58.87 (54.21–63.3) 58.55 (54.6–62.7) 0.65 Albumin (g/L) 37.36 (21.6–95.07) 35.91 (21.44–82.12) 0.63 DBIL (µmol/L) 17.16 (9.55–94.89) 15.58 (9.58–43.6) 0.665 IBIL (µmol/L) 17.16 (9.55–94.89) 15.58 (9.58–43.6) 0.665 IBIL (µmol/L) 18.88 (11.62–45.07) 18.06 (11.51–40.93) 0.76 IL (µmol/L) 18.88 (11.62–45.07) 18.06 (11.51–40.93) 0.76 BUN (mmol/L) 45.8 (3.6–5.91) 45.3 (3.4–5.47) 0.25 Sc (µmol/L) 236 (177–306) 244 (187–305) 0.74 VL/L) 236 (177–306) 244 (187–305) 0.74 VL (µmol/L) 16.3 (14.1–20.9)<	White blood cell(\times 10 ⁹ /L)	3.58 (2.35-5.34)	3.38 (2.26-5.28)	0.50
	Neutrophils($\times 10^9$ /L)	2.39 (1.5–3.82)	2.29 (1.42-3.77)	0.48
RBC (× 10 ¹² /L) 2.96 (2.45–3.57) 2.96 (2.49–3.59) 0.82 Hemoglobin (g/L) 91 (77–110) 91 (77–111) 0.91 Hemoglobin (g/L) 64 (39–111) 71 (43–108) 0.38 Total protein (g/L) 58.87 (54.21–63.3) 58.55 (54.6–6.27) 0.65 Albumin (g/L) 35.67 (31.87–39.02) 34.43 (32.32–37.49) 0.15 TBIL (µmol/L) 37.36 (21.6–95.07) 35.91 (21.44–82.12) 0.63 DBIL (µmol/L) 17.16 (9.55–49.89) 15.58 (9.58–43.6) 0.65 IBL (µmol/L) 17.16 (9.55–49.89) 15.58 (9.58–43.6) 0.65 IBL (µmol/L) 17.16 (9.55–49.89) 15.58 (9.58–43.6) 0.63 IBL (µmol/L) 17.16 (9.55–49.89) 15.58 (9.58–43.6) 0.63 IBL (µmol/L) 18.88 (11.62–45.07) 18.06 (11.51–40.93) 0.76 ALT (U/L) 27 (17–51) 26 (18–49) 0.71 ALT (U/L) 38 (25–74) 37 (25–61) 0.31 LDH (U/L) 189 (13.6–5.91) 4.5 (3.46–5.47) 0.25 SG (µmol/L) 26 (17–73 (6) 24 (187–305)	Lymphocyte(\times 10 ⁹ /L)	0.65 (0.4–1.06)	0.62 (0.41-0.98)	0.22
$\begin{array}{llllllllllllllllllllllllllllllllllll$	RBC (\times 10 ¹² /L)	2.96 (2.45–3.57)	2.96 (2.49–3.59)	0.82
Heratocrit (%) 26.9 (23-32) 27.1 (23.3-32.6) 0.76 Platelet (x 10 ⁰ /L) 64 (39-111) 71 (43-108) 0.38 Total protein (g/L) 35.87 (54.21-63.3) 58.55 (54.6-62.7) 0.65 Albumin (g/L) 37.36 (21.6-95.07) 35.91 (21.44-82.12) 0.63 DBIL (µmol/L) 17.16 (9.55-49.89) 15.58 (9.58-43.6) 0.65 IBIL (µmol/L) 17.16 (9.55-49.89) 15.58 (9.58-43.6) 0.65 IBIL (µmol/L) 17.16 (9.55-49.89) 15.58 (9.58-43.6) 0.65 IBIL (µmol/L) 18.88 (11.62-46.07) 18.06 (11.51-40.93) 0.71 AST (U/L) 27 (17-51) 26 (18-49) 0.71 AST (U/L) 159 (133-193) 164 (134-203) 0.31 LDH (U/L) 159 (136-5.91) 4.5 (3.6-5.47) 0.25 scr (µmol/L) 236 (177-306) 244 (187-305) 0.74 GFR (mL/min/L.73 m ²) 116.49 (93.66-151.55) 120.15 (90.35-147.30) 0.91 Prothrombin time (s) 16.3 (14.1-20.4) 16.3 (14.2-20.2) 0.95 Fibrinoggen (g/L) 1.70 (1.6-2.18)	Hemoglobin (g/L)	91 (77–110)	91 (77–111)	0.91
Platelet (× 10'/L)64 (39-11)// (43-108)0.38Total protein (g/L)58.87 (54.21-63.3)58.55 (54.6-62.7)0.65Albumin (g/L)35.67 (31.87-39.02)34.43 (32.32-37.49)0.15TBL (µmol/L)37.36 (21.6-95.07)35.91 (21.44-82.12)0.63DBL (µmol/L)17.16 (9.55-49.89)15.58 (9.58-43.6)0.65IBL (µmol/L)18.88 (11.62-45.07)18.06 (11.51-40.93)0.76ALT (U/L)27 (17-51)26 (18-49)0.71AST (U/L)38 (25-74)37 (25-61)0.31LDH (U/L)159 (133-193)164 (134-203)0.37BUN (mool/L)4.58 (36-5.91)4.5 (3.46-5.47)0.25Scr (µmol/L)04 (51-77)63 (50-77)0.93UA (µmol/L)236 (177-306)244 (187-305)0.74Prothrombin time (s)16.3 (14.1-20.4)16.3 (14.2-20.2)0.90INR1.42 (1.2-1.79)1.4 (1.2-1.82)0.95Fibriogen (g/L)1.57 (1.6-2.18)1.56 (1.07-2.22)0.51APTT (s)14.2 (367-56.1)43.3 (37.3-55.1)0.72Thrombin time (s)18.2 (16.5-20.2)18.2 (16.9-20.5)0.22DD (µg/L)790 (450-1970)830 (420-1660)0.76K ⁺ (mmol/L)107 (104-110)107 (104-110)0.71Graft factor11.2 (139.5-144)142 (140-144)0.91CT (mmol/L)100 (800-2000)1200 (800-2000)0.56Operation time (minutes)51 (42-58)50 (45-59)0.47Estimated GRWR2.00 (1.67-2.48)	Hematocrit (%)	26.9 (23–32)	27.1 (23.3–32.6)	0.76
Total protein (g/L) 58.67 (34.27-93.3) 58.53 (54.67-62.7) 0.05 Albumin (g/L) 35.67 (31.87-39.02) 34.43 (32.32-37.49) 0.15 TBIL (µmol/L) 37.36 (21.6-95.07) 35.91 (21.44-82.12) 0.63 DBIL (µmol/L) 17.16 (9.55-49.89) 15.58 (9.58-43.6) 0.65 ALT (U/L) 27 (17-51) 26 (18-49) 0.71 AST (U/L) 38 (25-74) 37 (25-61) 0.31 DBH (µmol/L) 458 (3.6-5.91) 4.5 (3.46-5.47) 0.25 SG (µmol/L) 458 (3.6-5.91) 4.5 (3.46-5.47) 0.25 SG (µmol/L) 4.58 (3.6-5.91) 4.5 (3.46-5.47) 0.25 SG (µmol/L) 236 (177-306) 244 (187-305) 0.74 eGFR (mL/min/L/3 m²) 1.62 (14.2-1.82) 0.95 0.95	Platelet (\times 10 ⁻⁷ L)	64 (39-111) 59 97 (54 21, 62 2)	/1 (43-108)	0.38
Albdinin (g/L) 33.00 (s1.6-95.02) 34.45 (s2.2-37.49) 0.13 TBL (µmol/L) 37.36 (s1.6-95.07) 35.49 (s2.2-37.49) 0.63 DBL (µmol/L) 17.16 (9.55-49.89) 15.58 (9.58-43.6) 0.65 IBL (µmol/L) 17.16 (9.55-49.89) 15.58 (9.58-43.6) 0.65 IBL (µmol/L) 18.88 (11.62-45.07) 18.06 (11.51-40.93) 0.76 ALT (U/L) 27 (17-51) 26 (18-49) 0.11 AST (U/L) 38 (25-74) 37 (25-61) 0.31 DUN (mmol/L) 458 (3.6-5.91) 4.5 (3.46-5.47) 0.25 sCr (µmol/L) 458 (3.6-5.91) 4.5 (3.46-5.47) 0.25 sCr (µmol/L) 236 (177.306) 244 (187-305) 0.91 Prothrombin time (s) 16.3 (14.1-20.4) 16.3 (14.2-20.2) 0.90 INR 14.2 (12-179) 1.4 (12-1.82) 0.95 Fibrinogen (g/L) 1.57 (11.6-2.18) 1.56 (10.7-2.22) 0.51 APTT (s) 14.2 (12-1.79) 1.4 (12-1.82) 0.95 Ribrinogen (g/L) 1.57 (11.6-2.18) 1.56 (10.7-2.22) 0.51 APTT (s) 14.82 (16.5-20.2) 18.2 (16.5-20.5)	Albumin (g/L)	25.67 (21.97, 20.02)	28.22 (24.0-02.7) 24.42 (22.22, 27.40)	0.05
Initial (unitable) Disc (1, 1, 1, 1, 2, 1, 2, 1, 1, 1, 1, 1, 1, 2, 1, 2, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	TBIL (umol/L)	37 36 (21 6-95 07)	34.45 (32.32-37.49) 35 91 (21 44-82 12)	0.13
IBL (µmol/L) 18.88 (11.62–45.07) 18.06 (11.51–40.93) 0.76 ALT (U/L) 27 (17–51) 26 (18–49) 0.71 AST (U/L) 138 (25–74) 37 (25–61) 0.31 LDH (U/L) 159 (133–193) 164 (134–203) 0.37 BUN (mmol/L) 4.58 (3.6–5.91) 4.5 (3.46–5.47) 0.25 scr (µmol/L) 0.64 (51–77) 63 (50–77) 0.93 UA (µmol/L) 236 (177–306) 244 (187–305) 0.74 eGFR (mL/min/1.73 m²) 116.49 (93.66–151.55) 120.15 (90.35–147.30) 0.91 Prothrombin time (s) 16.3 (14.1–20.4) 16.3 (14.2–20.2) 0.90 INR 1.42 (1.2–1.79) 1.4 (1.2–1.82) 0.95 Fibrinogen (g/L) 1.57 (1.16–2.18) 1.56 (1.07–2.22) 0.51 APTT (s) 44.2 (36.7–56.1) 43.3 (37.3–55.1) 0.77 Thrombin time (s) 18.2 (16.5–20.2) 18.2 (16.9–20.5) 0.22 DD (µg/L) 790 (450–1970) 830 (420–1660) 0.76 K ⁺ (mmol/L) 13.8 (3.58–4.21) 3.87 (3.59–4.13) 0.59 Na ⁺ (mmol/L) 107 (104–110) 107 (104–110) <td< td=""><td>DBIL (umol/L)</td><td>17.16 (9.55–49.89)</td><td>15.58 (9.58–43.6)</td><td>0.65</td></td<>	DBIL (umol/L)	17.16 (9.55–49.89)	15.58 (9.58–43.6)	0.65
ALT (U/L) 27 (17-51) 26 (18-49) 0.71 AST (U/L) 38 (25-74) 37 (25-61) 0.31 LDH (U/L) 159 (133-193) 164 (134-203) 0.37 BUN (mmol/L) 4.58 (3.6-5.91) 4.5 (3.46-5.47) 0.25 sCr (µmol/L) 64 (51-77) 63 (50-77) 0.93 UA (µmol/L) 236 (177-306) 244 (187-305) 0.74 eGFR (mL/min/L,73 m ²) 116.49 (93.66-151.55) 120.15 (90.35-147.30) 0.91 Prothrombin time (s) 16.3 (14.1-20.4) 16.3 (14.2-20.2) 0.90 INR 1.42 (1.2-1.79) 1.4 (1.2-1.82) 0.95 Fibrinogen (g/L) 1.57 (1.16-2.18) 1.56 (1.07-2.22) 0.51 APTT (s) 44.2 (36.7-56.1) 43.3 (37.3-55.1) 0.77 Thrombin time (s) 18.2 (16.5-20.2) 18.2 (16.9-20.5) 0.22 DD (µg/L) 790 (450-1970) 830 (420-1660) 0.76 K ⁺ (mmol/L) 3.88 (3.58-4.21) 3.87 (3.59-4.13) 0.59 Na ⁺ (mmol/L) 107 (104-110) 107 (104-144) 0.91 <tr< td=""><td>IBIL (µmol/L)</td><td>18.88 (11.62–45.07)</td><td>18.06 (11.51–40.93)</td><td>0.76</td></tr<>	IBIL (µmol/L)	18.88 (11.62–45.07)	18.06 (11.51–40.93)	0.76
AST (U/L) 38 (25-74) 37 (25-61) 0.31 LDH (U/L) 159 (133-193) 164 (134-203) 0.37 BUN (mmol/L) 4.58 (3.6-5.91) 4.5 (3.46-5.47) 0.25 SCr (µmol/L) 64 (51-77) 63 (50-77) 0.93 UA (µmol/L) 236 (177-306) 244 (187-305) 0.74 eGFR (mL/min/1.73 m ²) 116.49 (93.66-151.55) 120.15 (90.35-147.30) 0.91 Prothrombin time (s) 16.3 (14.1-20.4) 16.3 (14.2-20.2) 0.90 INR 1.42 (1.2-1.79) 1.4 (1.2-1.82) 0.95 Fibrinogen (g/L) 1.57 (1.16-2.18) 1.56 (1.07-2.22) 0.51 APTT (s) 442 (36.7-56.1) 43.3 (37.3-55.1) 0.77 Thrombin time (s) 18.2 (16.5-20.2) 18.2 (16.9-20.5) 0.22 DD (µg/L) 790 (450-1970) 830 (420-1660) 0.76 K ⁺ (mmol/L) 3.88 (3.58-4.21) 3.87 (3.59-4.13) 0.59 Na ⁺ (mmol/L) 142 (139.5-144) 142 (140-144) 0.91 CI ⁻ (mmol/L) 107 (104-110) 0.72 0.58	ALT (U/L)	27 (17–51)	26 (18–49)	0.71
LDH (U/L) 159 (133–193) 164 (134–203) 0.37 BUN (mmol/L) 4.58 (3.6–5.91) 4.5 (3.46–5.47) 0.25 SCr (µmol/L) 64 (51–77) 63 (50–77) 0.93 UA (µmol/L) 236 (177–306) 244 (187–305) 0.74 eGFR (mL/min/1.73 m ²) 116.49 (93.66–151.55) 120.15 (90.35–147.30) 0.91 Prothrombin time (s) 16.3 (14.1–20.4) 16.3 (14.2–20.2) 0.90 INR 1.42 (1.2–1.79) 1.4 (1.2–1.82) 0.95 Fibrinogen (g/L) 1.57 (1.16–2.18) 1.56 (1.07–2.22) 0.51 APTT (s) 142 (136–56.1) 43.3 (37.3–55.1) 0.77 Thrombin time (s) 18.2 (16.5–20.2) 18.2 (16.9–20.5) 0.22 DD (µg/L) 790 (450–1970) 830 (420–1660) 0.76 K ⁺ (mmol/L) 3.88 (3.58–4.21) 3.87 (3.59–4.13) 0.59 Na ⁺ (mmol/L) 142 (139.5–144) 142 (140–144) 0.91 CI ⁻ (mmol/L) 107 (104–110) 107 (104–110) 0.72 Graft factor Estimated GRWR 2.00 (1.67–2.48) 2.0	AST (U/L)	38 (25–74)	37 (25–61)	0.31
BUN (mmol/L) 4.58 (3.6-5.91) 4.5 (3.46-5.47) 0.25 sCr (µmol/L) 64 (51-77) 63 (50-77) 0.93 UA (µmol/L) 236 (177-306) 244 (187-305) 0.74 eGFR (mL/min/1.73 m²) 116.49 (93.66-151.55) 120.15 (90.35-147.30) 0.91 Prothrombin time (s) 16.3 (14.1-20.4) 16.3 (14.2-20.2) 0.90 INR 1.42 (1.2-1.79) 1.4 (1.2-1.82) 0.95 Fibrinogen (g/L) 1.57 (1.16-2.18) 1.56 (1.07-2.22) 0.51 APTT (s) 44.2 (36.7-56.1) 43.3 (37.3-55.1) 0.77 Thrombin time (s) 18.2 (16.5-20.2) 18.2 (16.9-20.5) 0.22 DD (µg/L) 790 (450-1970) 830 (420-1660) 0.76 K ⁺ (mmol/L) 3.88 (3.58-4.21) 3.87 (3.59-4.13) 0.59 Na ⁺ (mmol/L) 142 (139.5-144) 142 (140-144) 0.91 Cl ⁻ (mmol/L) 107 (104-110) 107 (104-110) 0.72 Graft factor 2 2.00 (1.67-2.48) 2.04 (1.58-2.65) 0.58 Operation time (minutes) 490 (435-580) <t< td=""><td>LDH (U/L)</td><td>159 (133–193)</td><td>164 (134–203)</td><td>0.37</td></t<>	LDH (U/L)	159 (133–193)	164 (134–203)	0.37
$ \begin{array}{cccccc} {\rm SCr} (\mu {\rm mol}/L) & 64 (51-77) & 63 (50-77) & 0.93 \\ {\rm UA} (\mu {\rm mol}/L) & 236 (177-306) & 244 (187-305) & 0.74 \\ {\rm eGFR} ({\rm mL}/{\rm min}/1.73 {\rm m}^2) & 116.49 (93.66-151.55) & 120.15 (90.35-147.30) & 0.91 \\ {\rm Prothrombin time} (s) & 16.3 (14.1-20.4) & 16.3 (14.2-20.2) & 0.90 \\ {\rm INR} & 1.42 (1.2-1.79) & 1.4 (1.2-1.82) & 0.95 \\ {\rm Fibrinogen} (g/L) & 1.57 (1.16-2.18) & 1.56 (1.07-2.22) & 0.51 \\ {\rm APTT} (s) & 44.2 (36.7-6.1) & 43.3 (37.3-55.1) & 0.77 \\ {\rm Thrombin time} (s) & 18.2 (16.5-20.2) & 18.2 (16.9-20.5) & 0.22 \\ {\rm DD} (\mu g/L) & 790 (450-1970) & 830 (420-1660) & 0.76 \\ {\rm K}^+ ({\rm mmol}/L) & 3.88 (3.58-4.21) & 3.87 (3.59-4.13) & 0.59 \\ {\rm Na}^+ ({\rm mmol}/L) & 142 (139.5-144) & 142 (140-144) & 0.91 \\ {\rm CI}^- ({\rm mmol}/L) & 107 (104-110) & 107 (104-110) & 0.72 \\ {\rm Graft factor} & & & & & & & & & & & & & & & & & & &$	BUN (mmol/L)	4.58 (3.6–5.91)	4.5 (3.46–5.47)	0.25
UA (µmol/L) 236 (177-306) 244 (187-305) 0.74 eGFR (mL/min/1.73 m²) 116.49 (93.66-151.55) 120.15 (90.35-147.30) 0.91 Prothrombin time (s) 16.3 (14.1-20.4) 16.3 (14.2-20.2) 0.90 INR 1.42 (1.2-1.79) 1.4 (1.2-1.82) 0.95 Fibrinogen (g/L) 1.57 (1.16-2.18) 1.56 (1.07-2.22) 0.51 APTT (s) 44.2 (36.7-56.1) 43.3 (37.3-55.1) 0.77 Thrombin time (s) 18.2 (16.5-20.2) 18.2 (16.9-20.5) 0.22 DD (µg/L) 790 (450-1970) 830 (420-1660) 0.76 K ⁺ (mmol/L) 3.88 (3.58-4.21) 3.87 (3.59-4.13) 0.59 Na ⁺ (mmol/L) 107 (104-110) 107 (104-144) 0.91 CI ⁻ (nmol/L) 107 (104-110) 107 (104-110) 0.72 Graft factor Estimated GRWR 2.00 (1.67-2.48) 2.04 (1.58-2.65) 0.58 Operation details 90 (435-580) 490 (430-575) 0.97 Anhepatic time (minutes) 490 (435-580) 490 (430-575) 0.97 Anhepatic time (minutes) 51 (45-58) 50 (45-59) 0.47 Estimated blood l	sCr (µmol/L)	64 (51–77)	63 (50–77)	0.93
eGFR (mL/min/1./3 m ⁻)116.49 (93.66-151.55)120.15 (90.35-147.30)0.91Prothrombin time (s)16.3 (14.1-20.4)16.3 (14.2-20.2)0.90INR1.42 (1.2-1.79)1.4 (1.2-1.82)0.95Fibrinogen (g/L)1.57 (1.16-2.18)1.56 (1.07-2.22)0.51APTT (s)44.2 (36.7-56.1)43.3 (37.3-55.1)0.77Thrombin time (s)18.2 (16.5-20.2)18.2 (16.9-20.5)0.22DD (µg/L)790 (450-1970)830 (420-1660)0.76K ⁺ (mmol/L)3.88 (3.58-4.21)3.87 (3.59-4.13)0.59Na ⁺ (mmol/L)142 (139.5-144)142 (140-144)0.91Cl ⁻ (mmol/L)107 (104-110)107 (104-110)0.72Graft factorEstimated GRWR2.00 (1.67-2.48)2.04 (1.58-2.65)0.58Operation details90 (435-580)490 (430-575)0.97Anhepatic time (minutes)51 (45-58)50 (45-59)0.47Estimated blood loss (mL)1000 (800-2000)1200 (800-2000)0.56Blood loss pe body weight (mL/Kg)17.14 (10.53-33.3)17.65 (10.81-32.61)0.71	UA (μ mol/L)	236 (177–306)	244 (187–305)	0.74
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	eGFR (mL/min/1./3 m ²)	16.49 (93.66–151.55)	16.2 (14.2, 20.2)	0.91
Internation $1.42 (1.2^{-1}.9)$ $1.4 (1.2^{-1}.62)$ 0.53 Fibrinogen (g/L) $1.57 (1.16-2.18)$ $1.56 (1.07-2.22)$ 0.51 APTT (s) $44.2 (36.7-56.1)$ $43.3 (37.3-55.1)$ 0.77 Thrombin time (s) $18.2 (16.5-20.2)$ $18.2 (16.9-20.5)$ 0.22 DD (µg/L)790 (450-1970) $830 (420-1660)$ 0.76 K ⁺ (nmol/L) $3.88 (3.58-4.21)$ $3.87 (3.59-4.13)$ 0.59 Na ⁺ (nmol/L) $142 (139.5-144)$ $142 (140-144)$ 0.91 Cl ⁻ (nmol/L) $107 (104-110)$ $107 (104-110)$ 0.72 Graft factor $51 (45-58)$ $50 (45-59)$ 0.47 Estimated GRWR $51 (45-58)$ $50 (45-59)$ 0.47 Deration time (minutes) $51 (45-58)$ $50 (45-59)$ 0.47 Estimated blood loss (mL) $1000 (800-2000)$ $1200 (800-2000)$ 0.56 Blood loss per body weight (mL/Kg) $17.14 (10.53-33.33)$ $17.65 (10.81-32.61)$ 0.71		1 42 (1 2-1 70)	10.5 (14.2-20.2)	0.90
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Fibringgen (g/l)	1.42(1.2-1.79) 1 57 (1 16–2 18)	1.56 (1.07-2.22)	0.95
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	APTT (s)	44.2 (36.7–56.1)	43.3 (37.3–55.1)	0.77
DD (μg/L) 790 (450–1970) 830 (420–1660) 0.76 K ⁺ (nmol/L) 3.88 (3.58–4.21) 3.87 (3.59–4.13) 0.59 Na ⁺ (nmol/L) 142 (139.5–144) 142 (140–144) 0.91 Cl ⁻ (nmol/L) 107 (104–110) 107 (104–110) 0.72 Graft factor 5 5 0.58 Operation details 0 0.97 0.97 Anhepatic time (minutes) 490 (435–580) 490 (430–575) 0.97 Anhepatic time (minutes) 51 (45–58) 50 (45–59) 0.47 Estimated blood loss (mL) 1000 (800–2000) 1200 (800–2000) 0.56 Blood loss per body weight (mL/Kg) 17.14 (10.53–33.33) 17.65 (10.81–32.61) 0.71	Thrombin time (s)	18.2 (16.5–20.2)	18.2 (16.9–20.5)	0.22
K ⁺ (nmol/L) 3.88 (3.58–4.21) 3.87 (3.59–4.13) 0.59 Na ⁺ (nmol/L) 142 (139.5–144) 142 (140–144) 0.91 Cl ⁻ (nmol/L) 107 (104–110) 107 (104–110) 0.72 Graft factor 2.00 (1.67–2.48) 2.04 (1.58–2.65) 0.58 Operation details 0 0 0.97 Anhepatic time (minutes) 490 (435–580) 490 (430–575) 0.97 Anhepatic time (minutes) 51 (45–58) 50 (45–59) 0.47 Estimated blood loss (mL) 1000 (800–2000) 1200 (800–2000) 0.56 Blood loss per body weight (mL/Kg) 17.14 (10.53–33.33) 17.65 (10.81–32.61) 0.71	DD (μq/L)	790 (450–1970)	830 (420–1660)	0.76
Na ⁺ (mmol/L) 142 (139.5–144) 142 (140–144) 0.91 Cl ⁻ (mmol/L) 107 (104–110) 107 (104–110) 0.72 Graft factor 2.00 (1.67–2.48) 2.04 (1.58–2.65) 0.58 Operation details 90 (435–580) 490 (430–575) 0.97 Anhepatic time (minutes) 51 (45–58) 50 (45–59) 0.47 Estimated blood loss (mL) 1000 (800–2000) 1200 (800–2000) 0.56 Blood loss per body weight (mL/Kg) 17.14 (10.53–33.33) 17.65 (10.81–32.61) 0.71	K ⁺ (mmol/L)	3.88 (3.58-4.21)	3.87 (3.59-4.13)	0.59
CI ⁻ (mmol/L) 107 (104–110) 107 (104–110) 0.72 Graft factor Estimated GRWR 2.00 (1.67–2.48) 2.04 (1.58–2.65) 0.58 Operation details 0 0 0 0.97 0.97 Anhepatic time (minutes) 490 (435–580) 490 (430–575) 0.97 Anhepatic time (minutes) 51 (45–58) 50 (45–59) 0.47 Estimated blood loss (mL) 1000 (800–2000) 1200 (800–2000) 0.56 Blood loss per body weight (mL/Kg) 17.14 (10.53–33.33) 17.65 (10.81–32.61) 0.71	Na ⁺ (mmol/L)	142 (139.5–144)	142 (140–144)	0.91
Graft factor Estimated GRWR 2.00 (1.67–2.48) 2.04 (1.58–2.65) 0.58 Operation details 0	Cl [_] (mmol/L)	107 (104–110)	107 (104–110)	0.72
Estimated GRWR 2.00 (1.67–2.48) 2.04 (1.58–2.65) 0.58 Operation details Operation time (minutes) 490 (435–580) 490 (430–575) 0.97 Anhepatic time (minutes) 51 (45–58) 50 (45–59) 0.47 Estimated blood loss (mL) 1000 (800–2000) 1200 (800–2000) 0.56 Blood loss per body weight (mL/Kg) 17.14 (10.53–33.33) 17.65 (10.81–32.61) 0.71	Graft factor			
Operation details 490 (435–580) 490 (430–575) 0.97 Operation time (minutes) 51 (45–58) 50 (45–59) 0.47 Estimated blood loss (mL) 1000 (800–2000) 1200 (800–2000) 0.56 Blood loss per body weight (mL/Kg) 17.14 (10.53–33.33) 17.65 (10.81–32.61) 0.71	Estimated GRWR	2.00 (1.67–2.48)	2.04 (1.58–2.65)	0.58
Operation time (minutes) 490 (430-580) 490 (430-575) 0.97 Anhepatic time (minutes) 51 (45-58) 50 (45-59) 0.47 Estimated blood loss (mL) 1000 (800-2000) 1200 (800-2000) 0.56 Blood loss per body weight (mL/Kg) 17.14 (10.53-33.33) 17.65 (10.81-32.61) 0.71	Operation details	400 (425 500)	400 (400 575)	0.07
Contended on the (ninnetes) S1 (43-50) S0 (45-59) 0.47 Estimated blood loss (mL) 1000 (800-2000) 1200 (800-2000) 0.56 Blood loss per body weight (mL/Kg) 17.14 (10.53-33.33) 17.65 (10.81-32.61) 0.71	Operation time (minutes)	47U (435-58U) 51 (15 50)	49U (43U-5/5) 50 (45 50)	0.97
Blood loss per body weight (mL/Kg) 17.14 (10.53–33.33) 17.65 (10.81–32.61) 0.71	Estimated blood loss (ml.)	21 (42-28) 1000 (200_2000)	20 (43-29) 1200 (800_2000)	0.47
	Blood loss per body weight (mL/Kg)	17.14 (10.53–33.33)	17.65 (10.81–2000)	0.71
				(continued)

Table 1. Continued.

Characteristic	Development data ($n = 423$)	Validation data ($n = 153$)	<i>p</i> -Value
Intraoperative fluid administration			
Crystalloid (mL)	4360 (3545–5345)	4250 (3560-5100)	0.48
Colloid (mL)	0 (0-0)	0 (0-0)	0.36
Total liquid inflow (mL)	4530 (3670–5585)	4375 (3630–5130)	0.27
Intraoperative transfusion			
RBC (units)	8 (4–12.5)	7.5 (4–11)	0.29
FFP (mL)	1000 (770–1570)	1000 (800–1570)	0.76
Cryoprecipitate (units)	0 (0-0)	0 (0-0)	0.81
PLT (units)	0 (0-0)	0 (0-0)	0.69
Salvage blood (mL)	0 (0-0)	0 (0-0)	0.88
Intraoperative drugs			
Ulinastatin (million units)	0 (0-30)	0 (0-30)	0.50
Furosemide (mg)	20 (5–70)	40 (17–80)	0.002
Insulin (IU)	0 (0-8)	0 (0-10)	0.37
Postoperative parameter			
Peak AST (U/L)	1017 (658–1936)	1177 (727–2157)	0.052
Postoperative RRT (N,%)	28 (6.6%)	17 (11.1%)	0.081
Postoperative hospital stay (day)	24 (21–31)	24 (20–30)	0.90
Length of ICU stay (day)	4 (3–6)	4 (3–6)	0.54
Died in hospital $(N, \%)$	8 (5.2%)	12 (2.8%)	0.20
Secondary OLT (N,%)	2 (1.3%)	3 (0.7%)	0.61

Continuous variables are displayed as median and interquartile ranges.

BMI: Body mass index; MAP: Mean arterial pressure; LVEF: Left ventricular ejection fraction; MELD: Model for End-Stage Liver Disease; RBC: Red blood cell; TBIL: Serum total bilirubin; DBIL: Serum direct bilirubin; IBIL: Serum indirect bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LDH: Lactate dehydrogenase; BUN: Blood urea nitrogen; sCr: Serum creatinine; UA: Uric acid; eGFR: Estimated glomerular filtration rate; INR: International normalized ratio of prothrombin time; APTT: Activated partial thromboplastin time; DD: D dimer; GRWR: Graft-recipient body weight ratio; FFP: Fresh frozen plasma; Peak AST: AST peak value within first 24 h after OLT.

Table	2. ι	Jnivariable	and	multi	variab	le	logistic	regression	anal	ysis f	for	predictors	of	severe	AKI.
-------	-------------	-------------	-----	-------	--------	----	----------	------------	------	--------	-----	------------	----	--------	------

	U	nivariable logistic regressio	n	M	Multivariable logistic regression			
Variables	β	OR(95% CI)	p	β	OR(95% CI)	p		
Age	0.0121	1.01(0.99–1.03)	0.265					
BMI (Kg/m ²)	0.0857	1.09(1.03-1.15)	0.003	0.0965	1.10(1.04-1.17)	0.002		
MAP (mmHg)	0.0217	1.02(1.00-1.04)	0.021					
Hypertension	0.6206	1.86(1.04–3.32)	0.036	0.8451	2.32(1.22-4.45)	0.010		
MELD score	0.0326	1.03(1.00-1.06)	0.027					
Operate time (minutes)	0.0006	1.00(0.99–1.00)	0.342					
GRWR	-0.0749	0.93(0.88-0.98)	0.010					
Blood loss (mL)	0.0001	1.00(0.99–1.00)	0.080					
RBC transfusion (units)	0.0109	1.01(0.98-1.04)	0.432					
FFP transfusion (per 1000 mL)	0.3004	1.35 (1.05–1.73)	0.017	0.2943	1.34(1.03–1.75)	0.031		
Furosemide (per 100 mg)	0.4607	1.59(1.17–2.15)	0.003					
TBIL (µmol/L)	0.0014	1.00(1.00-1.00)	0.046					
DBIL (µmol/L)	0.0017	1.00(0.99–1.00)	0.127					
IBIL (µmol/L)	0.0045	1.00(1.00-1.01)	0.012					
BUN (mmol/L)	-0.0991	0.91(0.83-0.98)	0.024					
sCr (µmol/L)	-0.0348	0.97(0.95-0.98)	< 0.001	-0.0415	0.96(0.95-0.97)	< 0.001		
UA (µmol/L)	-0.0032	0.99(0.99-1.00)	0.002					
eGFR (ml/min/1.73 m ²)	0.0127	1.01(1.01–1.02)	< 0.001					
INR	0.0922	1.09(0.90-1.32)	0.344					
Fibrinogen (g/L)	-0.1940	0.82(0.66-1.03)	0.087					
APTT(s)	0.0105	1.01(1.00-1.02)	0.014					
Peak AST (per 1000 U/L)	0.2453	1.28(1.12-1.46)	<0.001					

OR: Odds ratio; Cl: Confidence interval; BMI: Body mass index; MAP: Mean arterial pressure; MELD: Model for End Stage Liver Disease; GRWR: Graft-recipient body weight ratio; RBC: Red blood cell; FFP: Fresh frozen plasma; TBIL: Serum total bilirubin; DBIL: Serum direct bilirubin; IBIL: Serum indirect bilirubin; BUN: Blood urea nitrogen; sCr: Serum creatinine; UA: Uric acid; eGFR: Estimated glomerular filtration rate; APTT: Activated partial thromboplastin time; peak AST: AST peak value within first 24 h after OLT.

was significantly longer in those with severe AKI (p = 0.002).

Long-term prognosis of patients with and without severe AKI

Based on the probability of severe AKI predicted by the nomogram model, we further divided the patients into

low- and high-risk groups with a cutoff value of 0.36. After a median follow-up period of 29.5 months (interquartile range: 16–52 months), the mortality was 28.4% and 15.6% in the high- and low-risk groups, respectively. Kaplan-Meier survival analysis with log-rank test showed that patients in the high-risk group had a significantly poorer long-term survival outcome than those in the low-risk group (HR 1.92, p < 0.01, Figure 5).



Figure 2. Nomogram for the prediction of severe AKI after OLT. Draw a vertical line toward the 'Points' axis to determine the points of each variable, add up the points and position it on the 'Total Points' axis. Draw a vertical line toward the 'Risk of severe AKI' axis to find the possibility of severe AKI after OLT. AKI: Acute kidney injury; BMI: Body mass index; sCr: Preoperative serum creatinine; FFP: Fresh frozen plasma.

Competing risk analysis showed that the incidence of CKD was significantly higher in the severe AKI group than the no severe AKI group after controlling for competitive mortality before CKD (HR 1.48, p = 0.039) (Figure 6). However, there was no statistical difference in the cumulative incidence of CKD between the high-and low-risk groups (p = 0.491).

Discussion

In this study, we have developed and validated a nomogram model for predicting severe AKI after OLT for the first time. With excellent discrimination and calibration, it can be applied immediately at the end of surgery, assisting clinicians to identify patients at high risk for severe AKI and make preventive and therapeutic measures in advance. The risk factors enrolled in our model could also be collected from other centers easily, demonstrating the generalizability of this nomogram. Besides, we further divided the patients into low- and high-risk groups based on the probability of severe AKI predicted by the nomogram model. Patients in the high-risk group had a significantly poorer long-term survival outcome than those in the low-risk group. Therefore, this nomogram can also be used to predict long-term survival in advance and assist clinicians to pay more attention to these recipients during follow-up.

Postoperative AKI is a common complication after OLT. According to a relatively lower diagnostic threshold of KDIGO criteria, 71.4%, 35.9%, and 7.8% of these 576 recipients developed AKI, severe AKI, and required postoperative RRT after OLT, respectively. These results were consistent with previous studies that used the same KDIGO criteria, interpreting the generalizability of this nomogram [7,28,32]. The in-hospital mortality of patients with severe AKI was 4.25 times that of patients without severe AKI. And ICU stay was significantly longer in the severe AKI group. As for long-term prognosis, we further divided the patients into high- and low-risk groups based on the nomogram model. Compared with the low-risk group, the survival rate of patients in the high-risk group was significantly lower. However, the prevalence of CKD was not statistically different between the high- and low-risk groups. This might be related to the low incidence of CKD and the short follow-up period in this study. And the significant difference in the mortality of patients between the two groups might affect these results. It was not unexpected that the cumulative risk of CKD was significantly higher in the severe AKI group, indicating that the severe kidney injury may be persistent, long-term, and subsequently contribute to the progression to CKD.

As mentioned above, severe AKI after OLT is an important risk factor for the short and long-term prognosis. However, neither pharmacological nor



Figure 3. The ROC curve of the model forecasting the occurrence of severe AKI after OLT. The area under the ROC curve (AUC) were 0.73 (95% CI: 0.68–0.78, p < 0.05) in the development cohort (A) and 0.81 (95% CI: 0.74–0.88, p < 0.05) in the validation cohort (B).

non-pharmacological interventions have shown any significant benefits in preventing AKI after OLT. It is necessary to identify patients who are at high risk for severe AKI so that earlier protective strategy can be implemented.

Based on the logistic regression analysis, a risk prediction nomogram was developed using routine perioperative parameters. The recipients' BMI, hypertension, preoperative sCr, and intraoperative FFP transfusion were identified as the independent risk factors for severe AKI. The strongest predictor in our model was hypertension. Hypertension has been a known risk factor for postoperative AKI. It was proposed that patients



Figure 4. Calibration plot of predicted probability of severe AKI predicted by the nomogram model vs. observed probability in the development cohort (A) (p > 0.05) and validation cohort (B) (p > 0.05).

developing AKI were more likely to have arterial hypertension preoperatively, of whom the variation of blood pressure may be more significant [13]. And the greater difference between baseline and intraoperative blood pressure might exacerbate intraoperative hemodynamic disturbances, which could promote the occurrence of AKI. In addition, as a recognized feature of CKD, preoperative hypertension may be related to more advanced preexisting renal damage, which in itself was a potential risk factor for AKI after OLT [33].

The second predictor was recipients' BMI, which was a known factor that increased the risk of AKI after OLT [7]. There were several explanations for the correlation. Firstly, obesity could lead to chronic mild inflammation associated with an increase in adipokines, which was reported to play an essential role in the pathogenesis of acute ischemia/reperfusion injury in the kidney. Adipokines could activate NF- κ B and increase the expression of some proinflammatory molecules, such as TNF- α , IL-6, MIP-2, and MCP-1, which would lead to the infiltration of neutrophils, T cells, and macrophages into the injured kidneys [34]. Secondly, patients with elevated BMI had more severe oxidative stress and



Figure 5. Patient survival after liver transplantation. Patients were divided into low-risk and high-risk groups at the probability value of 0.36 predicted by the nomogram. The long-term survival outcome was significantly poorer in the high-risk group than in the low-risk group (p < 0.05).



Figure 6. Cumulative incidence of CKD and competitive mortality in patients with and without severe AKI (p < 0.05).

endothelial dysfunction, which were more predictive of postoperative AKI than inflammatory markers [35]. In addition, as a component of metabolic syndrome and an important risk factor for hypertension, diabetes, CKD, and cardiovascular disease, obesity may provide insufficient reserve during surgery to cope with stressinduced renal hypoperfusion [36]. In other researches, the impact of BMI on severe AKI remains controversial because obese or emaciated are both harmful to postoperative recovery. Consistent with previous research conducted in this center [32], emaciation has no effect on severe AKI, which might be related to the characteristics of our study population. There were only 5.0% of patients assigned to the underweight group (BMI <18.5 kg/m²). And the mean value of BMI in this group was 17.3 kg/m², approaching the lower limit of normal weight (18.5 \leq BMI <25 kg/m²). Therefore, the influence of emaciation on severe AKI needs to be further analyzed by expanding the sample size.

Preoperative sCr level was significantly associated with the development of severe AKI after OLT. As reported previously, sCr was a key component of the MELD score, which also reflected the significance of renal function as a predictor for short-term survival in patients with liver disease. Nevertheless, there were still conflicting evidence regarding the impact of renal insufficiency before OLT on the development of AKI after OLT [37]. In this study, the preoperative sCr level was inversely associated with the occurrence of postoperative AKI. This result was consistent with previous studies [38,39]. One possible explanation for this phenomenon may be that in an era of increasing demand for organ transplants, high-quality grafts with a lower donor risk index were matched to the higher-risk recipients [40]. The discrepancy between the number of OLT candidates and the availability of liver grafts has led to the use of increasingly higher risk grafts that were not utilized in the past to reduce waiting list mortality [41]. More importantly, poor protein intake, reduced muscle mass, severe hyperbilirubinemia, volume expansion, and reduced liver synthesis of sCr are all contributed to the lower sCr level in liver disease [42], which possibly indicated that lower sCr may reflect more severe condition to some extent. Further researches are needed to confirm the specific mechanism.

The requirement for FFP during OLT was independently associated with post-OLT AKI, which was consistent with previous studies [28,43]. The reason for this result may be that recipients often experience massive blood loss due to portal hypertension and coagulation dysfunction during OLT. Additionally, coagulation dysfunction and fibrinolysis reflect severe hepatic IRI and early impaired graft function.

Although gender, diabetes mellitus, Child-Pugh score, and blood loss may be risk factors for AKI after OLT in several previous reports, they were not associated with the risk of severe AKI in this study [44,45]. The main reason may be related to the different endpoints between this and previous studies. However, as an important element of the MELD score and Child-Pugh score, the preoperative sCr level was incorporated into the final model. And the intraoperative FFP transfusion which reflected the abnormal coagulation mechanism was related to the blood loss. These results are consistent with several previous studies, suggesting that the MELD score, Child-Pugh score, and blood loss by themselves may not contribute to the development of severe AKI independently. As an indicator of renal

and liver function before surgery, the sCr level may be more representative in predicting postoperative severe AKI. Furthermore, this could also be the result of the homogenization of our population with relatively low MELD scores, low prevalence of diabetes mellitus, and the majority of recipients were male in this study.

Finally, a nomogram was constructed based on the logistic regression analysis. It provided clinicians with a visual tool to understand the impact of predictors on the outcomes of postoperative severe AKI. We can accurately calculate the probabilities of severe AKI for individuals, making the results more personalized. The high AUC indicated the nomogram model has a strong ability to distinguish between patients with and without severe AKI. The excellent calibration curve showed the accurate prediction ability of this model. In addition, this model could identify patients with poor long-term outcomes, assisting clinicians to formulate interventions in advance to improve the prognosis of patients. Furthermore, the long-term value of this nomogram is that it can guide OLT in the future. For patients preparing for liver transplantation, their BMI and blood pressure should be intervened to achieve the target levels as soon as possible to reduce the risk of severe AKI after OLT.

There were several prediction models for AKI after OLT. A risk score for AKI after OLT in a Korean center [46] and another one from a Chinese multicentre [3] both used the old RIFLE-criteria for classifying AKI, which have been replaced by the latest KDIGO standards over the past few years. A nomogram model for predicting AKI after OLT has also been developed in the past but the sample size was too small [13]. Another nomogram was constructed based on the intraoperative hepatic blood inflow (HBI) to identify posttransplant AKI from a Chinese center. Nevertheless, the HBI could not be easily acquired in other centers, which limited the general use of this model [47]. A new model score for recipients of deceased donor transplantation from two European centers has been developed to identify patients at risk for severe AKI after OLT. This model score had good discriminative ability but it has not been used in Chinese patients [28].

Compared with these models, this model had the following advantages. In this study, the sample size was large enough and AKI was determined according to the KDIGO definition, which was reported to provide better prognostic capacity than the RIFLE and AKIN definitions [48]. Based on the perioperative variables that can be easily acquired, we constructed a nomogram model and validated it in the development and validation cohort, respectively. It was proved that this nomogram model has a strong discriminative ability and accurate predictive ability. Moreover, this prediction model could be used immediately at the end of operation, assisting clinicians to recognize recipients at high risk for severe AKI and poor long-term prognosis in advance. By considering early RRT and adjusting immunosuppression for these patients, the prognosis of the kidney may be improved. Furthermore, this new model was simple and easy to be popularized.

This study had several limitations. Firstly, this study was a retrospective single-center design, which should be evaluated in a prospective cohort in our center or in other centers to demonstrate its applicability. Secondly, the recipient, graft, and perioperative factors contributing to AKI have been analyzed, but the information of the donor was not included due to the privacy protection policy for the donor and recipient in our center. Thirdly, due to the difficulty in data collection, the relationship between other factors and postoperative AKI were did not analyzed, such as intraoperative hemodynamic parameter, dosage or duration of drug treatment, intraoperative and postoperative urine output. Moreover, postoperative transfusions, infection, and usage of contrast agents which would affect the incidence of AKI should also be included in the future. Besides, to accurately clarify the impact of AKI on the long-term prognosis after OLT, it is necessary to conduct a longer follow-up study.

Conclusion

With excellent discrimination and calibration, a new nomogram model for predicting severe AKI after OLT was successfully developed and validated. It can be applied immediately at the end of the surgery, assisting clinicians to identify patients at high risk for severe AKI and poor long-term outcomes. By considering early RRT and adjusting the immunosuppression strategy in advance, the kidney prognosis may be improved.

Author contributions

Dandan Guo was participated in the design of study, collection and analysis of data, and draft of the manuscript. Huifang Wang, Xiaoying Lai, and Junying Li were contributed to the performance of research and modification of the draft. Demin Xie and Li Zhen were participated in the performance of the research and contribution of analytic tools. Chunhui Jiang and Min Li were independent members who collected the data. Xuemei Liu was the senior author of this manuscript and contributed to the study design, implementation, manuscript draft, and critical revision of the paper. All authors were involved in the decision to submit this draft for publication.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by Error! Hyperlink reference not valid. under Grant number 19-6-1-18-nsh and the Scientific Research Project "Clinical Medicine + X" of the Medical Department of Qingdao University under Grant number 2018-21.Project of Science and Technology of Qingdao People's Livelihood (19-6-1-18-nsh); Scientific Research Project "Clinical Medicine + X" of Medical Department of Qingdao University (2018–21).

References

- [1] Kollmann D, Neong SF, Rosales R, et al. Renal dysfunction after liver transplantation: effect of donor type. Liver Transpl. 2020;26(6):799–810.
- [2] Lee YS, Choi YJ, Park KH, et al. Liver transplant patients with high levels of preoperative serum ammonia are at increased risk for postoperative acute kidney injury: a retrospective study. J Clin Med. 2020; 9(6):1629.
- [3] Zongyi Y, Baifeng L, Funian Z, et al. Risk factors of acute kidney injury after orthotopic liver transplantation in China. Sci Rep. 2017;7:41555.
- [4] Barri YM, Sanchez EQ, Jennings LW, et al. Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl. 2009;15(5):475–483.
- [5] Kalisvaart M, De Haan JE, Hesselink DA, et al. The postreperfusion syndrome is associated with acute kidney injury following donation after brain death liver transplantation. Transpl Int. 2017;30(7):660–669.
- [6] Trinh E, Alam A, Tchervenkov J, et al. Impact of acute kidney injury following liver transplantation on longterm outcomes. Clin Transplant. 2017;31(1):e12863.
- [7] Kalisvaart M, Schlegel A, Umbro I, et al. The impact of combined warm ischemia time on development of acute kidney injury in donation after circulatory death liver transplantation: stay within the golden hour. Transplantation. 2018;102(5):783–793.
- [8] Bao B, Wang W, Wang Y, et al. A prediction score model and survival analysis of acute kidney injury following orthotopic liver transplantation in adults. Ann Palliat Med. 2021;10(6):6168–6179.
- [9] Kalisvaart M, Schlegel A, Trivedi PJ, et al. Chronic kidney disease after liver transplantation: impact of extended criteria grafts. Liver Transpl. 2019;25(6): 922–933.
- [10] Thanapongsatorn P, Chaikomon K, Lumlertgul N, et al. Comprehensive versus standard care in post-severe acute kidney injury survivors, a randomized controlled trial. Crit Care. 2021;25(1):322.
- [11] Lin J, Ji XJ, Wang AY, et al. Timing of continuous renal replacement therapy in severe acute kidney injury patients with fluid overload: a retrospective cohort study. J Crit Care. 2021;64:226–236.

- [12] Summary of recommendation statements. Kidney Int Suppl (2011). 2012;2(1):8–12.
- [13] Rueggeberg A, Boehm S, Napieralski F, et al. Development of a risk stratification model for predicting acute renal failure in orthotopic liver transplantation recipients. Anaesthesia. 2008;63(11):1174–1180.
- [14] Utsumi M, Umeda Y, Sadamori H, et al. Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria. Transpl Int. 2013;26(8): 842–852.
- [15] Wyssusek KH, Keys AL, Yung J, et al. Evaluation of perioperative predictors of acute kidney injury post orthotopic liver transplantation. Anaesth Intensive Care. 2015;43(6):757–763.
- [16] Tokodai K, Lannsjö C, Kjaernet F, et al. Association of post-reperfusion syndrome and ischemia-reperfusion injury with acute kidney injury after liver transplantation. Acta Anaesthesiol Scand. 2020;64(6):742–750.
- [17] Xu L, Li C, Zhao L, et al. Acute kidney injury after nephrectomy: a new nomogram to predict postoperative renal function. BMC Nephrol. 2020;21(1):181.
- [18] Guan C, Li C, Xu L, et al. Risk factors of cardiac surgery-associated acute kidney injury: development and validation of a perioperative predictive nomogram. J Nephrol. 2019;32(6):937–945.
- [19] Zhang P, Guan C, Li C, et al. A visual risk assessment tool for acute kidney injury after intracranial aneurysm clipping surgery. Ren Fail. 2020;42(1):1093–1099.
- [20] KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2: 1–138.
- [21] Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–470.
- [22] Hannon V, Kothari RP, Zhang L, et al. The association between vena cava implantation technique and acute kidney injury after liver transplantation. Transplantation. 2020;104(11):e308–e316.
- [23] Peng JC, Li YJ, Wang J, et al. Incidence of chronic kidney disease after orthotopic liver transplantation in a Chinese cohort. Clin Exp Nephrol. 2020;24(9):806–812.
- [24] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304): 957–980.
- [25] Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118(3):201–210.
- [26] Mizota T, Hamada M, Matsukawa S, et al. Relationship between intraoperative hypotension and acute kidney injury after living donor liver transplantation: a retrospective analysis. J Cardiothorac Vasc Anesth. 2017; 31(2):582–589.
- [27] Baron-Stefaniak J, Schiefer J, Miller EJ, et al. Comparison of macrophage migration inhibitory factor and neutrophil gelatinase-associated lipocalin-2 to predict acute kidney injury after liver transplantation: an observational pilot study. PLoS One. 2017;12(8): e0183162.

- [28] Kalisvaart M, Schlegel A, Umbro I, et al. The AKI prediction score: a new prediction model for acute kidney injury after liver transplantation. HPB (Oxford). 2019;21(12):1707–1717.
- [29] Yap WK, Shih MC, Kuo C, et al. Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases. JAMA Netw Open. 2018;1(6):e183242.
- [30] Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27(17):2800–2808.
- [31] Zhou ZQ, Fan LC, Zhao X, et al. Risk factors for acute kidney injury after orthotopic liver transplantation: a single-center data analysis. J Huazhong Univ Sci Technol Med Sci. 2017;37(6):861–863.
- [32] Zhou J, Lyu L, Zhu L, et al. Association of overweight with postoperative acute kidney injury among patients receiving orthotopic liver transplantation: an observational cohort study. BMC Nephrol. 2020;21(1): 223.
- [33] Caragata R, Wyssusek KH, Kruger P. Acute kidney injury following liver transplantation: a systematic review of published predictive models. Anaesth Intensive Care. 2016;44(2):251–261.
- [34] Oh J, Rabb H. Adiponectin: an enlarging role in acute kidney injury. Kidney Int. 2013;83(4):546–548.
- [35] Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007;116(11):1234–1241.
- [36] Kwakernaak AJ, Toering TJ, Navis G. Body mass index and body fat distribution as renal risk factors: a focus on the role of renal haemodynamics. Nephrol Dial Transplant. 2013;28 Suppl 4:iv42–iv49.
- [37] De Haan JE, Hoorn EJ, De Geus HRH. Acute kidney injury after liver transplantation: Recent insights and future perspectives. Best Pract Res Clin Gastroenterol. 2017;31(2):161–169.
- [38] Kim SG, Larson JJ, Lee JS, et al. Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl. 2017;23(6):733–740.
- [39] Mrzljak A, Franusic L, Pavicic-Saric J, et al. Pre- and intraoperative predictors of acute kidney injury after liver transplantation. World J Clin Cases. 2020;8(18): 4034–4042.
- [40] Rahman S, Davidson BR, Mallett SV. Early acute kidney injury after liver transplantation: Predisposing factors and clinical implications. WJH. 2017;9(18):823–832.
- [41] Jochmans I, Meurisse N, Neyrinck A, et al. Hepatic ischemia/reperfusion injury associates with acute kidney injury in liver transplantation: prospective cohort study. Liver Transpl. 2017;23(5):634–644.
- [42] Agarwal B, Davenport A. Difficulties in diagnosing acute kidney injury post liver transplantation using serum creatinine based diagnostic criteria. World J Hepatol. 2014;6(10):696–703.

- [43] Guo M, Gao Y, Wang L, et al. Early acute kidney injury associated with liver transplantation: a retrospective case-control study. Med Sci Monit. 2020;26:e923864.
- [44] Hilmi IA, Damian D, Al-Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth. 2015;114(6):919–926.
- [45] Durand F, Francoz C, Asrani SK, et al. Acute kidney injury after liver transplantation. Transplantation. 2018;102(10):1636–1649.
- [46] Park MH, Shim HS, Kim WH, et al. Clinical risk scoring models for prediction of acute kidney injury

after living donor liver transplantation: a retrospective observational study. PLoS One. 2015;10(8): e0136230.

- [47] Jiao A, Liu Q, Li F, et al. Intraoperative hepatic blood inflow can predict early acute kidney injury following DCD liver transplantation: a retrospective observational study. Biomed Res Int. 2019;2019:4572130.
- [48] Tsai TY, Chien H, Tsai FC, et al. Comparison of RIFLE, AKIN, and KDIGO classifications for assessing prognosis of patients on extracorporeal membrane oxygenation. J Formos Med Assoc. 2017;116(11): 844–851.